NDAORALCAPSULE
Approved
Sep 2024
Lifecycle
Growth
Competitive Pressure
0/100
Clinical Trials
4
Data completeness
6/8 — Strong
COBENFY (xanomeline and trospium chloride) by Bristol Myers Squibb is cholinergic muscarinic agonists [moa]. First approved in 2024.
Drug data last refreshed 21h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
COBENFY is an oral capsule combining xanomeline and trospium chloride, approved September 2024 as a novel cholinergic muscarinic agonist. It represents the first-in-class combination targeting cholinergic pathways for psychiatric indications. The dual mechanism leverages muscarinic agonism while managing anticholinergic side effects through trospium co-formulation.
Growth13.1 years to LOE
Early-stage growth product with zero competitive pressure presents significant opportunity for field teams and commercial strategists to establish market position and build patient base.
Mechanism of Action
Cholinergic Muscarinic Agonists
Pharmacologic Class:
Cholinergic Muscarinic Agonist
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (4)
A Prospective, Observational, Single-Arm, Multicenter Real-World Study Evaluating the Treatment Pattern, Safety and Effectiveness of Xanomeline and Trospium Chloride Capsules (KarXT) in the Treatment of Chinese Adult Participants With Schizophrenia
Started Sep 2026
250 enrolled
Schizophrenia Disorder
A PET/MRI Study of Cobenfy on Dopamine Transmission in Schizophrenia
Started Jul 2026
12 enrolled
SCHIZOPHRENIA 1 (Disorder)Schizoaffecitve Disorder
Long-Term Real-World Safety of Cobenfy in Adults With Schizophrenia
Started May 2026
3,000 enrolled
Schizophrenia
Effectiveness and Adverse-effect Switch Evaluation of Xanomeline and Trospium Chloride (KarXT)
Started Feb 2026
1,500 enrolled
Schizophrenia
Worked on COBENFY at Bristol Myers Squibb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.